Member Exclusive
NEWS ROUND-UP
Cell therapy weekly: Novo Nordisk continues to investigate stem cell therapies for chronic diseases and Kite expands manufacturing capability
This week: FDA accepts IND for gene-edited sickle cell therapy and severe hemophilia A patients targeted in phase I/II study.
Please sign in or register for FREE
Sign in to RegMedNet

Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
- Connect and collaborate with other members
- Post about your own research, share your take on key topics and more
No comments yet.